COVID-19
Session: Poster Session A
Sudhir Venkatesan, PhD, MPH
Director
BPM Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca
Cambridge, United Kingdom
Samah Hayek, DrPH
Clalit Research Institute, Innovation Division, Clalit Health Services
Tel Aviv, Israel
Joseph Levy, PhD
Clalit Community Division, Clalit Health Services
Tel Aviv, Israel
Galit Shaham, PhD
Clalit Research Institute, Innovation Division, Clalit Health Services
Tel Aviv, Israel
Noa Dagan, MD, PhD
Clalit Research Institute, Innovation Division, Clalit Health Services
Tel Aviv, Israel
Danielle Serby, MA
Clalit Community Division, Clalit Health Services
Tel Aviv, Israel
Hadar Duskin-Bitan, MD
Clalit Community Division, Clalit Health Services
Tel Aviv, Israel
Adva Yarden, MD
Medical Affairs, BioPharmaceuticals Medical, AstraZeneca
Kfar-Saba, Israel
Cátia Ferreira, PhD
Vaccines and Immune Therapies Unit, BioPharmaceuticals Medical, AstraZeneca
Wilmington, United States
Idit Livnat, PhD
Medical Affairs, BioPharmaceuticals Medical, AstraZeneca
Kfar-Saba, Israel
Sabada Dube, PhD, MPH
Epidemiology, Vaccines and Immune Therapies Unit, AstraZeneca
Cambridge, United Kingdom
Mario Ouwens, PhD
BPM Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca
Gothenburg, Sweden
Sylvia Taylor, PhD, MPH, MBA
Senior Director, Epidemiology
Medical Evidence, Vaccines and Immune Therapies Unit, AstraZeneca
Cambridge, United Kingdom
Ran D. Balicer, MD, PhD
Clalit Research Institute, Innovation Division, Clalit Health Services
Tel Aviv, Israel
Doron Netzer, MD
Medical Affairs, BioPharmaceuticals Medical, AstraZeneca
Kfar-Saba, Israel
Alon Peretz, MD
Medical Affairs, BioPharmaceuticals Medical, AstraZeneca
Kfar-Saba, Israel